Clostridial neurotoxins: Mode of substrate recognition and novel therapy development

Current Protein and Peptide Science

Volumn 15, Issue 5, 2014, Pages 490-503

  Chen, Sheng ^a  

^a HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

Botulinum toxins (BoNTs); Clostridial neurotoxins (CNTs); Novel therapy development; Substrate recognition

Indexed keywords

BACTERIAL TOXIN; BOTULINUM TOXIN; CLOSTRIDIAL NEUROTOXIN; SYNAPTOBREVIN 2; TETANUS TOXIN; UNCLASSIFIED DRUG; ANTITOXIN; PROTEIN BINDING;

BACTERIAL TRANSLOCATION; CELL MIGRATION; ENZYME ACTIVITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MOLECULAR BIOLOGY; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; STRUCTURE ANALYSIS; SUBSTRATE RECOGNITION; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DEVELOPMENT; METABOLISM; MOLECULAR GENETICS; PROCEDURES; PROTEIN TERTIARY STRUCTURE; PROTEIN TRANSPORT;

AMINO ACID SEQUENCE; ANTITOXINS; DRUG DISCOVERY; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; TETANUS TOXIN;

EID: 84904514372     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/13892037113146660086     Document Type: Review

References (120)

1. Cherington, M. Clinical spectrum of botulism. Muscle Nerve, 1998, 21(6), 701-710.
2. Dembek, Z.F.; Smith, L.A.; Rusnak, J.M. Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities. Disaster Med. Public Health Prep., 2007, 1(2), 122-134.
3. Schiavo, G.; Rossetto, O.; Benfenati, F.; Poulain, B.; Montecucco, C. Tetanus and botulinum neurotoxins are zinc proteases specific for components of the neuroexocytosis apparatus. Ann. N. Y. Acad. Sci., 1994, 710, 65-75.
4. Montecucco, C.; Schiavo, G. Mechanism of action of tetanus and botulinum neurotoxins. Mol. Microbiol., 1994, 13(1), 1-8.
5. Poulain, B.; Humeau, Y. Mode of action of botulinum neurotoxin: pathological, cellular and molecular aspect. Ann. Readapt. Med. Phys., 2003, 46(6), 265-275.
6. Davletov, B.; Bajohrs, M.; Binz, T. Beyond BOTOX: advantages and limitations of individual botulinum neurotoxins. Trends Neurosci., 2005, 28(8), 446-452.
7. Arnon, S.S.; Schechter, R.; Inglesby, T.V.; Henderson, D.A.; Bartlett, J.G.; Ascher, M.S.; Eitzen, E.; Fine, A.D.; Hauer, J.; Layton, M.; Lillibridge, S.; Osterholm, M.T.; O'Toole, T.; Parker, G.; Perl, T.M.; Russell, P.K.; Swerdlow, D.L.; Tonat, K.; Working Group on Civilian Biodefense. Botulinum toxin as a biological weapon: medical and public health management. JAMA., 2001, 285(8), 1059-1070.
8. Pickett, A.; Perrow, K. Towards new uses of botulinum toxin as a novel therapeutic tool. Toxins (Basel), 2011, 3(1), 63-81.
9. Bullens, R.W.; O'Hanlon, G.M.; Wagner, E.; Molenaar, P.C.; Furukawa, K.; Plomp, J.J.; Willison, H.J. Complex gangliosides at the neuromuscular junction are membrane receptors for autoantibodies and botulinum neurotoxin but redundant for normal synaptic function. J. Neurosci., 2002, 22(16), 6876-6884.
10. Kitamura, M.; Igimi, S.; Furukawa, K. Different response of the knockout mice lacking b-series gangliosides against botulinum and tetanus toxins. Biochim. Biophys. Acta., 2005, 1741(1-2), 1-3.
11. Rummel, A.; Eichner, T.; Weil, T.; Karnath, T.; Gutcaits, A.; Mahrhold, S.; Sandhoff, K.; Proia, R.L.; Acharya, K.R.; Bigalke, H.; Binz, T. Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. Proc. Natl. Acad. Sci. U S A, 2007, 104(1), 359-364.
12. Tsukamoto, K.; Kohda, T.; Mukamoto, M.; Takeuchi, K.; Ihara, H.; Saito, M.; Kozaki, S. Binding of Clostridium botulinum type C and D neurotoxins to ganglioside and phospholipid. Novel insights into the receptor for clostridial neurotoxins. J. Biol. Chem., 2005, 280(42), 35164-35171.
13. Marxen, P.; Fuhrmann, U.; Bigalke, H. Gangliosides mediate inhibitory effects of tetanus and botulinum A neurotoxins on exocytosis in chromaffin cells. Toxicon., 1989, 27(8), 849-859.
14. Marxen, P.; Erdmann, G.; Bigalke, H. The translocation of botulinum A neurotoxin by chromaffin cells is promoted in low ionic strength solution and is insensitive to trypsin. Toxicon., 1991, 29(2), 181-189.
15. Kozaki, S.; Kamata, Y.; Watarai, S.; Nishiki, T.; Mochida, S. Ganglioside GT1b as a complementary receptor component for Clostridium botulinum neurotoxins. Microb. Pathog., 1998, 25(2), 91-99.
16. Dong, M.; Richards, D.A.; Goodnough, M.C.; Tepp, W.H.; Johnson, E.A.; Chapman, E.R. Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J. Cell Biol., 2003, 162(7), 1293-1303.
17. Nishiki, T.; Kamata, Y.; Nemoto, Y.; Omori, A.; Ito, T.; Takahashi, M.; Kozaki, S. Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J. Biol. Chem., 1994, 269(14), 10498-10503.
18. Dong, M.; Tepp, W.H.; Liu, H.; Johnson, E.A.; Chapman, E.R. Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons. J. Cell Biol., 2007, 179(7), 1511-1522.
19. Peng, L.; Berntsson, R.P.; Tepp, W.H.; Pitkin, R.M.; Johnson, E.A.; Stenmark, P.; Dong, M. Botulinum neurotoxin D-C uses synaptotagmin I/II as receptors and human synaptotagmin II is not an effective receptor for type B, D-C, and G toxins. J. Cell Sci., 2012, 125(Pt 13), 3233-3242.
20. Dong, M.; Yeh, F.; Tepp, W.H.; Dean, C.; Johnson, E.A.; Janz, R.; Chapman, E.R. SV2 is the protein receptor for botulinum neurotoxin A. Science, 2006, 312(5773): 592-596.
21. Dong, M.; Liu, H.; Tepp, W.H.; Johnson, E.A.; Janz, R.; Chapman, E.R. Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol. Biol. Cell, 2008, 19(12), 5226-5237.
22. Fu, Z.; Chen, C.; Barbieri, J.T.; Kim, J.J.; Baldwin, M.R. Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F. Biochemistry, 2009, 48(24), 5631-5641.
23. Peng, L.; Tepp, W.H.; Johnson, E.A.; Dong, M. Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. PLoS Pathog., 2011, 7(3), e1002008.
24. Brunger, A.T.; Rummel, A. Receptor and substrate interactions of clostridial neurotoxins. Toxicon., 2009, 54(5), 550-560.
25. Binz, T.; Rummel, A. Cell entry strategy of clostridial neurotoxins. J. Neurochem., 2009, 109(6), 1584-1595.
26. Fischer, A.; Montal, M. Single molecule detection of intermediates during botulinum neurotoxin translocation across membranes. Proc. Natl. Acad. Sci. U S A, 2007, 104(25), 10447-10452.
27. Montal, M. Translocation of botulinum neurotoxin light chain protease by the heavy chain protein-conducting channel. Toxicon., 2009, 54(5), 565-569.
28. Brunger, A.T.; Breidenbach, M.A.; Jin, R.; Fischer, A.; Santos, J.S.; Montal, M. Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain. PLoS Pathog., 2007, 3(9), 1191-1194.
29. Fischer, A.; Montal, M. Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes. J. Biol. Chem., 2007, 282(40), 29604-29611.
30. Fernandez-Salas, E.; Steward, L.E.; Ho, H.; Garay, P.E.; Sun, S.W.; Gilmore, M.A.; Ordas, J.V.; Wang, J.; Francis, J.; Aoki, K.R. Plasma membrane localization signals in the light chain of botulinum neurotoxin. Proc. Natl. Acad. Sci. U S A, 2004, 101(9), 3208-3213.
31. Tsai, Y.C.; Maditz, R.; Kuo, C.L.; Fishman, P.S.; Shoemaker, C.B.; Oyler, G.A.; Weissman, A.M. Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc. Natl. Acad. Sci. U S A, 2010, 107(38), 16554-16559.
32. Chen, S.; Barbieri, J.T. Association of botulinum neurotoxin serotype A light chain with plasma membrane-bound SNAP-25. J. Biol. Chem., 2011, 286(17), 15067-15072.
33. Wang, J.; Zurawski, T.H.; Meng, J.; Lawrence, G.; Olango, W.M.; Finn, D.P.; Wheeler, L.; Dolly, J.O. A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic. J. Biol. Chem., 2011, 286(8), 6375-6385.
34. Kistner, A.; Habermann, E. Reductive cleavage of tetanus toxin and botulinum neurotoxin A by the thioredoxin system from brain. Evidence for two redox isomers of tetanus toxin. Naunyn. Schmiedebergs Arch. Pharmacol., 1992, 345(2), 227-234.
35. Schiavo, G.; Rossetto, O.; Santucci, A.; DasGupta, B.R.; Montecucco, C. Botulinum neurotoxins are zinc proteins. J. Biol. Chem., 1992, 267(33), 23479-23483.
36. Schiavo, G.; Poulain, B.; Rossetto, O.; Benfenati, F.; Tauc, L.; Montecucco, C. Tetanus toxin is a zinc protein and its inhibition of neurotransmitter release and protease activity depend on zinc. EMBO J., 1992, 11(10), 3577-3583.
37. Schiavo, G.; Benfenati, F.; Poulain, B.; Rossetto, O.; Polverino de Laureto, P.; DasGupta, B.R.; Montecucco, C. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature, 1992, 359(6398), 832-835.
38. Schiavo, G.; Shone, C.C.; Rossetto, O.; Alexander, F.C.; Montecucco, C. Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin. J. Biol. Chem., 1993, 268(16), 11516-11519.
39. Sollner, T.; Whiteheart, S.W.; Brunner, M.; Erdjument-Bromage, H.; Geromanos, S.; Tempst, P.; Rothman, J.E. SNAP receptors implicated in vesicle targeting and fusion. Nature, 1993, 362(6418), 318-324.
40. Doellgast, G.J.; Triscott, M.X.; Beard, G.A.; Bottoms, J.D.; Cheng, T.; Roh, B.H.; Roman, M.G.; Hall, P.A.; Brown, J.E. Sensitive enzyme-linked immunosorbent assay for detection of Clostridium botulinum neurotoxins A, B, and E using signal amplification via enzyme-linked coagulation assay. J. Clin. Microbiol., 1993, 31(9), 2402-2409.
41. Williamson, L.C.; Halpern, J.L.; Montecucco, C.; Brown, J.E.; Neale, E.A. Clostridial neurotoxins and substrate proteolysis in intact neurons: botulinum neurotoxin C acts on synaptosomalassociated protein of 25 kDa. J. Biol. Chem., 1996, 271(13), 7694-7699.
42. Schiavo, G.; Shone, C.C.; Bennett, M.K.; Scheller, R.H.; Montecucco, C. Botulinum neurotoxin type C cleaves a single Lys-Ala bond within the carboxyl-terminal region of syntaxins. J. Biol. Chem., 1995, 270(18), 10566-10570.
43. Sutton, R.B.; Fasshauer, D.; Jahn, R.; Brunger, A.T. Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution. Nature, 1998, 395(6700), 347-353.
44. Ekong, T.A.; Feavers, I.M.; Sesardic, D. Recombinant SNAP-25 is an effective substrate for Clostridium botulinum type A toxin endopeptidase activity in vitro. Microbiol., 1997, 143(Pt 10), 3337-3347.
45. Yamasaki, S.; Baumeister, A.; Binz, T.; Blasi, J.; Link, E.; Cornille, F.; Roques, B.; Fykse, E.M.; Sudhof, T.C.; Jahn, R., et al. Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin. J. Biol. Chem., 1994, 269(17), 12764-12772.
46. Cornille, F.; Martin, L.; Lenoir, C.; Cussac, D.; Roques, B.P.; Fournie-Zaluski, M.C. Cooperative exosite-dependent cleavage of synaptobrevin by tetanus toxin light chain. J. Biol. Chem.,1997, 272(6), 3459-3464.
47. Yamasaki, S.; Binz, T.L.; Hayashi, T.; Szabo, E.; Yamasaki, N.; Eklund, M.; Jahn, R.; Niemann, H. Botulinum neurotoxin type G proteolyses the Ala81-Ala82 bond of rat synaptobrevin 2. Biochem. Biophys. Res. Commun., 1994, 200(2), 829-835.
48. Vaidyanathan, V.V.; Yoshino, K.; Jahnz, M.; Dorries, C.; Bade, S.; Nauenburg, S.; Niemann, H.; Binz, T. Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E: domains and amino acid residues controlling the formation of enzyme-substrate complexes and cleavage. J. Neurochem., 1999, 72(1), 327-337.
49. Rossetto, O.; Schiavo, G.; Montecucco, C.; Poulain, B.; Deloye, F.; Lozzi, L.; Shone, C.C. SNARE motif and neurotoxins. Nature, 1994, 372(6505), 415-416.
50. Washbourne, P.; Pellizzari, R.; Baldini, G.; Wilson, M.C.; Montecucco, C. Botulinum neurotoxin types A and E require the SNARE motif in SNAP-25 for proteolysis. FEBS Lett., 1997, 418(1-2), 1-5.
51. Chen, S.; Barbieri, J.T. Unique substrate recognition by botulinum neurotoxins serotypes A and E. J. Biol. Chem., 2006, 281(16), 10906-10911.
52. Chen, S.; Hall, C.; Barbieri, J.T. Substrate recognition of VAMP-2 by botulinum neurotoxin B and tetanus neurotoxin. J. Biol. Chem., 2008, 283(30), 21153-21159.
53. Sikorra, S.; Henke, T.; Galli, T.; Binz, T. Substrate recognition mechanism of VAMP/synaptobrevin-cleaving clostridial neurotoxins. J. Biol. Chem., 2008, 283(30), 21145-21152.
54. Jin, R.; Sikorra, S.; Stegmann, C.M.; Pich, A.; Binz, T.; Brunger, A.T. Structural and biochemical studies of botulinum neurotoxin serotype C1 light chain protease: implications for dual substrate specificity. Biochemistry, 2007, 46(37), 10685-10693.
55. Silvaggi, N.R.; Boldt, G.E.; Hixon, M.S.; Kennedy, J.P.; Tzipori, S.; Janda, K.D.; Allen, K.N. Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with smallmolecule inhibitors highlight active-site flexibility. Chem. Biol., 2007, 14(5), 533-542.
56. Arndt, J.W.; Chai, Q.; Christian, T.; Stevens, R.C. Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity. Biochemistry, 2006, 45(10), 3255-3262.
57. Agarwal, R.; Binz, T.; Swaminathan, S. Structural analysis of botulinum neurotoxin serotype F light chain: implications on substrate binding and inhibitor design. Biochemistry, 2005, 44(35), 11758-11765.
58. Arndt, J.W.; Yu, W.; Bi, F.; Stevens, R.C. Crystal structure of botulinum neurotoxin type G light chain: serotype divergence in substrate recognition. Biochemistry, 2005, 44(28), 9574-9580.
59. Agarwal, R.; Binz, T.; Swaminathan, S. Analysis of active site residues of botulinum neurotoxin E by mutational, functional, and structural studies: Glu335Gln is an apoenzyme. Biochemistry, 2005, 44(23), 8291-8302.
60. Breidenbach, M.A.; Brunger, A.T. 2.3 A crystal structure of tetanus neurotoxin light chain. Biochemistry, 2005, 44(20), 7450-7457.
61. Breidenbach, M.A.; Brunger, A.T. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature, 2004, 432(7019), 925-929.
62. Agarwal, R.; Schmidt, J.J.; Stafford, R.G.; Swaminathan, S. Mode of VAMP substrate recognition and inhibition of Clostridium botulinum neurotoxin F. Nat. Struct. Mol. Biol., 2009, 16(7), 789-794.
63. Chen, S.; Kim, J.J.; Barbieri, J.T. Mechanism of substrate recognition by botulinum neurotoxin serotype A. J. Biol. Chem., 2007, 282(13), 9621-9627.
64. Chen, S.; Barbieri, J.T. Multiple pocket recognition of SNAP25 by botulinum neurotoxin serotype E. J. Biol. Chem., 2007, 282(35), 25540-25547.
65. Hanson, M.A.; Stevens, R.C. Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 A resolution. Nat. Struct. Biol., 2000, 7(8), 687-692.
66. Chen, S.; Wan, H.Y. Molecular mechanisms of substrate recognition and specificity of botulinum neurotoxin serotype F. Biochem. J., 2011, 433(2), 277-284.
67. Chen, S.; Karalewitz, A.P.; Barbieri, J.T. Insights into the different catalytic activities of Clostridium neurotoxins. Biochemistry, 2012, 51(18), 3941-3947.
68. Sikorra, S.; Henke, T.; Swaminathan, S.; Galli, T.; Binz, T. Identification of the amino acid residues rendering TI-VAMP insensitive toward botulinum neurotoxin B. J. Mol. Biol., 2006, 357(2), 574-582.
69. Cheng, C.M.; Chen, J.S.; Patel, R.P. Unlabeled uses of botulinum toxins: a review, part 2. Am. J. Health Syst. Pharm., 2006, 63(3), 225-232.
70. Glogau, R.G. Review of the use of botulinum toxin for hyperhidrosis and cosmetic purposes. Clin. J. Pain, 2002, 18(6 Suppl), S191-197.
71. Sadoul, K.; Berger, A.; Niemann, H.; Weller, U.; Roche, P.A.; Klip, A.; Trimble, W.S.; Regazzi, R.; Catsicas, S.; Halban, P.A. SNAP-23 is not cleaved by botulinum neurotoxin E and can replace SNAP-25 in the process of insulin secretion. J. Biol. Chem., 1997, 272(52), 33023-33027.
72. Jahn, R.; Scheller, R.H. SNAREs--engines for membrane fusion. Nat. Rev. Mol. Cell Biol., 2006, 7(9), 631-643.
73. Davis, C.W.; Dickey, B.F. Regulated airway goblet cell mucin secretion. Annu. Rev. Physiol., 2008, 70, 487-512.
74. Foster, K.A.; Adams, E.J.; Durose, L.; Cruttwell, C.J.; Marks, E.; Shone, C.C.; Chaddock, J.A.; Cox, C.L.; Heaton, C.; Sutton, J.M.; Wayne, J.L.; Alexander, F.C.; Rogers, D.F. Re-engineering the target specificity of Clostridial neurotoxins-a route to novel therapeutics. Neurotox. Res., 2006, 9(2-3), 101-107.
75. Rogers, D.F. Physiology of airway mucus secretion and pathophysiology of hypersecretion. Respir. Care, 2007, 52(9), 1134-1146; discussion 1146-1139.
76. Hickson, G.R.; Chamberlain, L.H.; Maier, V.H.; Gould, G.W. Quantification of SNARE protein levels in 3T3-L1 adipocytes: implications for insulin-stimulated glucose transport. Biochem. Biophys. Res. Commun., 2000, 270(3), 841-845.
77. Saxena, S.K.; George, C.M.; Pinskiy, V.; McConnell, B. Epithelial sodium channel is regulated by SNAP-23/syntaxin 1A interplay. Biochem. Biophys. Res. Commun., 2006, 343(4), 1279-1285.
78. Chen, D.; Bernstein, A.M.; Lemons, P.P.; Whiteheart, S.W. Molecular mechanisms of platelet exocytosis: role of SNAP-23 and syntaxin 2 in dense core granule release. Blood, 2000, 95(3), 921-929.
79. Martin-Martin, B.; Nabokina, S.M.; Blasi, J.; Lazo, P.A.; Mollinedo, F. Involvement of SNAP-23 and syntaxin 6 in human neutrophil exocytosis. Blood, 2000, 96(7), 2574-2583.
80. Reales, E.; Mora-Lopez, F.; Rivas, V.; Garcia-Poley, A.; Brieva, J.A.; Campos-Caro, A. Identification of soluble N-ethylmaleimidesensitive factor attachment protein receptor exocytotic machinery in human plasma cells: SNAP-23 is essential for antibody secretion. J. Immunol., 2005, 175(10), 6686-6693.
81. Pagan, J.K.; Wylie, F.G.; Joseph, S.; Widberg, C.; Bryant, N.J.; James, D.E.; Stow, J.L. The t-SNARE syntaxin 4 is regulated during macrophage activation to function in membrane traffic and cytokine secretion. Curr. Biol., 2003, 13(2), 156-160.
82. Castle, J.D.; Guo, Z.; Liu, L. Function of the t-SNARE SNAP-23 and secretory carrier membrane proteins (SCAMPs) in exocytosis in mast cells. Mol. Immunol., 2002, 38(16-18), 1337-1340.
83. Paumet, F.; Le Mao, J.; Martin, S.; Galli, T.; David, B.; Blank, U.; Roa, M. Soluble NSF attachment protein receptors (SNAREs) in RBL-2H3 mast cells: functional role of syntaxin 4 in exocytosis and identification of a vesicle-associated membrane protein 8-containing secretory compartment. J. Immunol., 2000, 164(11), 5850-5857.
84. Chaddock, J.A.; Purkiss, J.R.; Alexander, F.C.; Doward, S.; Fooks, S.J.; Friis, L.M.; Hall, Y.H.; Kirby, E.R.; Leeds, N.; Moulsdale, H.J.; Dickenson, A.; Green, G.M.; Rahman, W.; Suzuki, R.; Duggan, M.J.; Quinn, C.P.; Shone, C.C.; Foster, K.A. Retargeted clostridial endopeptidases: inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain. Mov. Disord., 2004, 19(Suppl 8), S42-47.
85. Duggan, M.J.; Quinn, C.P.; Chaddock, J.A.; Purkiss, J.R.; Alexander, F.C.; Doward, S.; Fooks, S.J.; Friis, L.M.; Hall, Y.H.; Kirby, E.R.; Leeds, N.; Moulsdale, H.J.; Dickenson, A.; Green, G.M.; Rahman, W.; Suzuki, R.; Shone, C.C.; Foster, K.A. Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. J. Biol. Chem., 2002, 277(38), 34846-34852.
86. Foster, K.A. A new wrinkle on pain relief: re-engineering clostridial neurotoxins for analgesics. Drug Discov. Today, 2005, 10(8), 563-569.
87. Yamamoto, H.; Ida, T.; Tsutsuki, H.; Mori, M.; Matsumoto, T.; Kohda, T.; Mukamoto, M.; Goshima, N.; Kozaki, S.; Ihara, H. Specificity of botulinum protease for human VAMP family proteins. Microbiol. Immunol., 2012, 56(4), 245-253.
88. Chen, S.; Barbieri, J.T. Engineering botulinum neurotoxin to extend therapeutic intervention. Proc. Natl. Acad. Sci. U S A, 2009, 106(23), 9180-9184.
89. Goschel, H.; Wohlfarth, K.; Frevert, J.; Dengler, R.; Bigalke, H. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences. Exp. Neurol., 1997, 147(1), 96-102.
90. Atassi, M.Z.; Oshima, M. Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins. Crit. Rev. Immunol., 1999, 19(3), 219-260.
91. Dolimbek, B.Z.; Jankovic, J.; Atassi, M.Z. Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol. Invest., 2002, 31(3-4), 247-262.
92. Atassi, M.Z.; Dolimbek, B.Z. Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A. Protein J., 2004, 23(1), 39-52.
93. Atassi, M.Z. Basic immunological aspects of botulinum toxin therapy. Mov. Disord., 2004, 19(Suppl 8), S68-S84.
94. Jankovic, J. Botulinum toxin in clinical practice. J. Neurol. Neurosurg. Psychiatry, 2004, 75(7), 951-957.
95. Jankovic, J. Treatment of cervical dystonia with botulinum toxin. Mov. Disord, 2004, 19(Suppl 8), S109-115.
96. Jankovic, J.; Vuong, K.D.; Ahsan, J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology, 2003, 60(7), 1186-1188.
97. Jankovic, J. Botulinum toxin therapy for cervical dystonia. Neurotox. Res., 2006, 9(2-3), 145-148.
98. Brashear, A.; Lew, M.F.; Dykstra, D.D.; Comella, C.L.; Factor, S.A.; Rodnitzky, R.L.; Trosch R.; Singer, C.; Brin, M.F.; Murray, J.J.; Wallace, J.D.; Willmer-Hulme, A.; Koller, M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type Aresponsive cervical dystonia. Neurology, 1999, 53(7), 1439-1446.
99. Aoki, K.R. Immunologic and other properties of therapeutic botulinum toxin serotypes. In: Brin, M.F.; Hallett, M.; Jankovic, J. (Eds), Scientific and Therapeutic Aspects of Botulinum Toxin. Lippincott Willams & Wilkins, Philadephia, pp. 103-113. 2002.
100. Swope, D.; Barbano, R. Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia. Neurologic. Clinics, 2008, 26(Suppl 1), 54-65.
101. Comella, C.L. The treatment of cervical dystonia with botulinum toxins. J. Neural. Transm., 2008, 115(4), 579-583.
102. Foster, K.A. Engineered toxins: new therapeutics. Toxicon., 2009, 54(5), 587-592.
103. Foran, P.; Shone, C.C.; Dolly, J.O. Differences in the protease activities of tetanus and botulinum B toxins revealed by the cleavage of vesicle-associated membrane protein and various sized fragments. Biochemistry, 1994, 33(51), 15365-15374.
104. Ahmed, S.A.; Olson, M.A.; Ludivico, M.L.; Gilsdorf, J.; Smith, L.A. Identification of residues surrounding the active site of type A botulinum neurotoxin important for substrate recognition and catalytic activity. Protein J., 2008, 27(3), 151-162.
105. Atassi, M.Z.; Jankovic, J.; Steward, L.E.; Aoki, K.R.; Dolimbek, B.Z. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule. Immunobiology, 2012, 217(1), 17-27.
106. Atassi, M.Z.; Dolimbek, B.Z.; Jankovic, J.; Steward, L.E.; Aoki, K.R. Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol. Immunol. 2008, 45(15), 3878-3888.
107. Dolimbek, B.Z.; Aoki, K.R.; Steward, L.E.; Jankovic, J.; Atassi, M.Z. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol. Immunol., 2007, 44(5), 1029-1041.
108. Dolimbek, B.Z.; Aoki, K.R.; Atassi, M.Z. Reduction of antibody response against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol-peptide conjugates. Immunol. Lett., 2011, 137(1-2), 46-52.
109. Pang, Y.P.; Davis, J.; Wang, S.; Park, J.G.; Nambiar, M.P.; Schmidt, J.J.; Millard, C.B. Small molecules showing significant protection of mice against botulinum neurotoxin serotype A. PLoS One, 2010, 5(4), e10129.
110. Roxas-Duncan, V.; Enyedy, I.; Montgomery, V.A.; Eccard, V.S.; Carrington, M.A.; Lai, H.; Gul, N.; Yang, D.C.; Smith, L.A. Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A. Antimicrob. Agents Chemother., 2009, 53(8), 3478-3486.
111. Hermone, A.R.; Burnett, J.C.; Nuss, J.E.; Tressler, L.E.; Nguyen, T.L.; Solaja, B.A.; Vennerstrom, J.L.; Schmidt, J.J.; Wipf, P.; Bavari, S.; Gussio, R. Three-dimensional database mining identifies a unique chemotype that unites structurally diverse botulinum neurotoxin serotype A inhibitors in a three-zone pharmacophore. ChemMedChem, 2008, 3(12), 1905-1912.
112. Tang, J.; Park, J.G.; Millard, C.B.; Schmidt, J.J.; Pang, Y.P. Computer-aided lead optimization: improved small-molecule inhibitor of the zinc endopeptidase of botulinum neurotoxin serotype A. PLoS One, 2007, 2(1), e761.
113. Lai, H.; Feng, M.; Roxas-Duncan, V.; Dakshanamurthy, S.; Smith, L.A.; Yang, D.C. Quinolinol and peptide inhibitors of zinc protease in botulinum neurotoxin A: effects of zinc ion and peptides on inhibition. Arch. Biochem. Biophys., 2009, 491(1-2), 75-84.
114. Silhar, P.; Capkova, K.; Salzameda, N.T.; Barbieri, J.T.; Hixon, M.S.; Janda, K.D. Botulinum neurotoxin A protease: discovery of natural product exosite inhibitors. J. Am. Chem. Soc., 2010, 132(9), 2868-2869.
115. Zuniga, J.E.; Hammill, J.T.; Drory, O.; Nuss, J.E.; Burnett, J.C.; Gussio, R.; Wipf, P.; Bavari, S.; Brunger, A.T. Iterative structurebased peptide-like inhibitor design against the botulinum neurotoxin serotype A. PLoS One, 2010, 5(6), e11378.
116. Kumaran, D.; Rawat, R.; Ludivico, M.L.; Ahmed, S.A.; Swaminathan, S. Structure-and substrate-based inhibitor design for Clostridium botulinum neurotoxin serotype A. J. Biol. Chem., 2008, 283(27), 18883-18891.
117. Burnett, J.C.; Ruthel, G.; Stegmann, C.M.; Panchal, R.G.; Nguyen, T.L.; Hermone, A.R.; Stafford, R.G.; Lane, D.J.; Kenny, T.A.; McGrath, C.F.; Wipf, P.; Stahl, A.M.; Schmidt, J.J.; Gussio, R.; Brunger, A.T.; Bavari, S. Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons. J. Biol. Chem., 2007, 282(7), 5004-5014.
118. Schmidt, J.J.; Stafford, R.G.; Bostian, K.A. Type A botulinum neurotoxin proteolytic activity: development of competitive inhibitors and implications for substrate specificity at the S1' binding subsite. FEBS Lett., 1998, 435(1), 61-64.
119. Zuniga, J.E.; Schmidt, J.J.; Fenn, T.; Burnett, J.C.; Arac, D.; Gussio, R.; Stafford, R.G.; Badie, S.S.; Bavari, S.; Brunger, A.T. A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate. Structure, 2008, 16(10), 1588-1597.
120. Hale, M.; Oyler, G.; Swaminathan, S.; Ahmed, S.A. Basic tetrapeptides as potent intracellular inhibitors of type A botulinum neurotoxin protease activity. J. Biol. Chem., 2011, 286(3), 1802-1811.